186 related articles for article (PubMed ID: 16103101)
1. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
5. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
7. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
[TBL] [Abstract][Full Text] [Related]
10. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
11. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
12. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.
Wu X; Liang H; O'Hara KA; Yalowich JC; Hasinoff BB
Chem Res Toxicol; 2008 Feb; 21(2):483-93. PubMed ID: 18197631
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
14. A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.
Kondapi AK; Satyanarayana N; Saikrishna AD
Arch Biochem Biophys; 2006 Jun; 450(2):123-32. PubMed ID: 16712776
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
Toyoda E; Kurosawa A; Kamekawa H; Adachi N
Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952
[TBL] [Abstract][Full Text] [Related]
17. The topopyrones poison human DNA topoisomerases I and II.
Khan QA; Elban MA; Hecht SM
J Am Chem Soc; 2008 Oct; 130(39):12888-9. PubMed ID: 18774813
[TBL] [Abstract][Full Text] [Related]
18. Alternariol acts as a topoisomerase poison, preferentially affecting the IIalpha isoform.
Fehr M; Pahlke G; Fritz J; Christensen MO; Boege F; Altemöller M; Podlech J; Marko D
Mol Nutr Food Res; 2009 Apr; 53(4):441-51. PubMed ID: 18727009
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
20. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]